Results 51 to 60 of about 1,300 (156)

French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics

Fundamental &Clinical Pharmacology, Volume 40, Issue 1, January 2026.
ABSTRACT Background The implementation of pharmacogenetics in clinical practice increasingly relies on multigene panels. Objectives The objective of this study is to develop harmonized recommendations for the design and analytical implementation of multigene pharmacogenetic panels, defining clinically relevant genes and associated regions of interest ...
Nicolas Picard, Estelle Ayme‐Dietrich, Sylvie Quaranta, Tiphaine Adam‐De‐Beaumais, Abd El Kader Ait Tayeb, Hugo Alarcan, Dorra Amor, David Barthelemy, Mouna Ben Sassi, Séverine Cunat, Mouna Daldoul, Hervé Delacour, Marie‐Christine Etienne‐Grimaldi, Xavier Fonrose, Benjamin Hennart, Louis Lebreton, Stephanie Malard, Céline Narjoz, Asma Omezzine, Nicolas Pallet, Léa Payen, Jeanne Petit, Fabienne Thomas, Sameh Trabelsi, Camille Tron, Céline Verstuyft, Paul Vilquin, Jean‐Christophe Boyer, Vincent Haufroid, French‐Speaking Network of Pharmacogenetics (RNPGx)   +29 more
wiley   +1 more source

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Samira Merali, David H. Salinger, Maria Palmisano, Amy J. Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amit Roy, Vidya Perera   +9 more
doaj   +1 more source

Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction

Open Heart
Background Hypertrophic cardiomyopathy (HCM) is characterised by abnormal thickening of ventricular myocardium. Left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients, causing progressive symptoms, heart failure and mortality ...
Jane Draper, Antonio De Marvao, Robert M Cooper, Gerry Carr-White, Nabeel Sheikh, Rachel Bastiaenen, Yande Kasolo, Jason N Dungu, Edward Burford   +8 more
doaj   +1 more source

Mavacamten for hypertrophic obstructive cardiomyopathy [PDF]

The Lancet, 2021
Eduard, Quintana, Pietro, Bajona, Patrick O, Myers   +2 more
openaire   +2 more sources

Unveiling Mid‐Cavity Obstruction in Hypertrophic Cardiomyopathy: A Case‐Based Approach

Case Reports in Cardiology, Volume 2026, Issue 1, 2026.
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing myocardial hypertrophy, sometimes leading to mid‐cavity obstruction (MCO), which can be underdiagnosed based solely on noninvasive imaging. Case summary A 52‐year‐old male with exertional dyspnea and chest pain showed apical hypertrophy on echocardiography, with a mid‐cavity ...
Anass Maaroufi, Nicolas Verheyen, Judit Andreka, Gabor G. Toth, Stefan Harb, Michael Lichtenauer   +5 more
wiley   +1 more source

Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Milind Y. Desai, Andrew Gaballa, Yuichiro Okushi, Mohammed Abusafia, Shada Jadam, Katy Rutkowski, Susan Ospina, Sanaa Sultana, Maran Thamilarasan, Craig Asher, Zoran B. Popovic, Bo Xu   +11 more
doaj   +1 more source

The Central Role of Echocardiography in Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Comprehensive Review

Cardiology Research and Practice, Volume 2026, Issue 1, 2026.
Mavacamten is a cardiac myosin inhibitor used in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Echocardiography is central to selecting suitable patients, confirming left ventricular outflow tract (LVOT) obstruction, excluding inappropriate use when left ventricular ejection fraction (LVEF) is < 55% and guiding dose titration ...
Ali Nizam, Ibrahim Antoun, Liz Hodson, G. André Ng, Harshil Dhutia, Satabdi Datta Choudhury   +5 more
wiley   +1 more source

Heart failure reporting signals associated with concomitant mavacamten and CYP inhibitors in obstructive hypertrophic cardiomyopathy: a real-world pharmacovigilance study with propensity score matching

Frontiers in Pharmacology
BackgroundMavacamten, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (HOCM), carries a risk of excessive negative inotropy.
Daqiu Chen, Yanqing Wu, Zhanxiong Xie, Wenchao Qiu, Xiaomai Huang, Shanghua Xu, Shunxiang Luo   +6 more
doaj   +1 more source

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +1 more source

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk

JACC: Case Reports
Background: Treatment and accurate assessment of aortic valve stenosis (AS) with concomitant obstructive hypertrophic cardiomyopathy (HCM) prove challenging.
Omar M. Abdelfattah, MD, Robyn Bryde, MD, Kutaiba Nazif, MD, Matthew W. Martinez, MD   +3 more
doaj   +1 more source